Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) – Pipeline Review, H2 2016’, provides in depth analysis on Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted pipeline therapeutics.

The report provides comprehensive information on the Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF)

The report reviews Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics and enlists all their major and minor projects

The report assesses Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Amgen Inc.

AnGes MG, Inc.

F-star Biotechnology Limited

Kringle Pharma, Inc.

M3 Biotechnology, Inc.

Minerva Biotechnologies Corporation

Molecular Partners AG

ViroMed Co., Ltd.

Yooyoung Pharmaceutical Co., Ltd.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) Overview 7

Therapeutics Development 8

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Products under Development by Stage of Development 8

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Products under Development by Therapy Area 9

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Products under Development by Indication 10

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Pipeline Products Glance 12

Late Stage Products 12

Early Stage Products 13

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Products under Development by Companies 14

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Products under Development by Universities/Institutes 17

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Therapeutics Assessment 19

Assessment by Monotherapy/Combination Products 19

Assessment by Mechanism of Action 20

Assessment by Route of Administration 22

Assessment by Molecule Type 24

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Companies Involved in Therapeutics Development 26

Amgen Inc. 26

AnGes MG, Inc. 27

F-star Biotechnology Limited 28

Kringle Pharma, Inc. 29

M3 Biotechnology, Inc. 30

Minerva Biotechnologies Corporation 31

Molecular Partners AG 32

ViroMed Co., Ltd. 33

Yooyoung Pharmaceutical Co., Ltd. 34

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Drug Profiles 35

beperminogene perplasmid - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

FS-101 - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

Gene Therapy to Activate HGF for Myocardial Infarction - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

Gene Therapy to Antagonize HGF for Rheumatoid Arthritis and Hepatocellular Carcinoma - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

MM-201 - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

Monoclonal Antibodies to Inhibit Hepatocyte Growth Factor for Metastatic Cancer - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

MP-0250 - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

NK-4 - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

rilotumumab - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

SL-186 - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

SL-188 - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

VM-202 - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

YYB-101 - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Dormant Projects 57

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Discontinued Products 59

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Featured News & Press Releases 60

Sep 20, 2016: F-star to present data on FS-101 at Upcoming AACR Conferences 60

Sep 08, 2016: ViroMed proceeding with the World’s first phase III gene therapy clinical trial for diabetic peripheral neuropathy 60

Aug 02, 2016: VM BioPharma Announces Korea Food and Drug Administration Approval of Phase 2 Clinical Trial for Investigational Gene Therapy VM202 in Ischemic Heart Disease 61

Jun 27, 2016: VM BioPharma Announces First Patient Dosed in Phase 3 Study of Gene Therapy Candidate, VM202, in Painful Diabetic Peripheral Neuropathy 61

Jun 20, 2016: AnGes Announces Amendment to the Global Development of HGF Plasmid for Critical Limb Ischemia 62

May 18, 2016: VM BioPharma Announces FDA Fast Track Designation Granted for Investigational Gene Therapy VM202 for Patients with Amyotrophic Lateral Sclerosis 63

Apr 15, 2016: AnGes Completes Patient Enrollment for Phase 1/2 Clinical Trials of Gene Therapy with HGF Plasmid in Primary Lymphedema 64

Jan 22, 2016: ViroMed Publishes Results from Critical Limb Ischemia Phase II Clinical Study 64

Jan 08, 2016: Molecular Partners to Conduct Phase II Trial of MP0250, a Multi-DARPin Targeting VEGF and HGF, in Multiple Myeloma 65

Nov 07, 2015: Research Presented at AACR-NCI-EORTC Shows Good Tolerability and Sustained Systemic Exposure of MP0250, a Multi-DARPin Targeting VEGF and HGF, in Patients with Advanced Cancer 66

Oct 27, 2015: First clinical data of multi-DARPin MP0250 to be presented at the AACR-NCI-EORTC oncology conference 67

Sep 01, 2015: US FDA Approves Initiation of ViroMed's VM202 for Phase III Clinical Study of Chronic Non-Healing Ischemic Diabetic Foot Ulcer 68

Aug 12, 2015: Patient Enrollment Begins in Europe in the Global Phase III Clinical Trial of HGF Gene Therapy for Critical Limb Ischemia 69

Mar 06, 2015: ViroMed dba VM BioPharma: A Phase II Study Done at Northwestern Hospital Shows Potential Relief for Diabetics with Painful Condition 69

Nov 24, 2014: Amgen Announces Termination Of All Amgen-Sponsored Clinical Studies Of Rilotumumab In Advanced Gastric Cancer 71

Appendix 72

Methodology 72

Coverage 72

Secondary Research 72

Primary Research 72

Expert Panel Validation 72

Contact Us 72

Disclaimer 73

List of Tables

List of Tables

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Indication, H2 2016 11

Comparative Analysis by Late Stage Development, H2 2016 12

Comparative Analysis by Early Stage Products, H2 2016 13

Number of Products under Development by Companies, H2 2016 14

Products under Development by Companies, H2 2016 15

Products under Development by Companies, H2 2016 (Contd..1) 16

Number of Products under Investigation by Universities/Institutes, H2 2016 17

Products under Investigation by Universities/Institutes, H2 2016 18

Assessment by Monotherapy/Combination Products, H2 2016 19

Number of Products by Stage and Mechanism of Action, H2 2016 21

Number of Products by Stage and Route of Administration, H2 2016 23

Number of Products by Stage and Molecule Type, H2 2016 25

Pipeline by Amgen Inc., H2 2016 26

Pipeline by AnGes MG, Inc., H2 2016 27

Pipeline by F-star Biotechnology Limited, H2 2016 28

Pipeline by Kringle Pharma, Inc., H2 2016 29

Pipeline by M3 Biotechnology, Inc., H2 2016 30

Pipeline by Minerva Biotechnologies Corporation, H2 2016 31

Pipeline by Molecular Partners AG, H2 2016 32

Pipeline by ViroMed Co., Ltd., H2 2016 33

Pipeline by Yooyoung Pharmaceutical Co., Ltd., H2 2016 34

Dormant Projects, H2 2016 57

Dormant Projects (Contd..1), H2 2016 58

Discontinued Products, H2 2016 59

List of Figures

List of Figures

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Top 10 Indication, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 12

Comparative Analysis by Early Stage Products, H2 2016 13

Assessment by Monotherapy/Combination Products, H2 2016 19

Number of Products by Mechanism of Actions, H2 2016 20

Number of Products by Stage and Mechanism of Actions, H2 2016 20

Number of Products by Routes of Administration, H2 2016 22

Number of Products by Stage and Routes of Administration, H2 2016 22

Number of Products by Molecule Types, H2 2016 24

Number of Products by Stage and Molecule Type, H2 2016 24

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports